Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD79b antibody-drug conjugate SHR-A1912

An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) conjugated to a topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-CD79b ADC SHR-A1912 targets and binds to CD79b expressed on tumor cells. Upon binding and internalization, the topoisomerase-1 inhibitor is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing CD79b. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC SHR-A1912
anti-CD79b ADC SHR-A1912
Code name:SHR A1912
SHR-A1912
SHRA1912
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search